Protocol Ledger

NCT05642442 · Phase II · COMPLETED

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Interventional Phase II clinical trial protocol NCT05642442 sponsored by Jazz Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-01 Enrollment: 169 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05642442
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)169 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05642442
Protocol FieldVerified Registry Value
NCT IdentifierNCT05642442
Consolidated Lead SponsorJazz Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment169 participants (ACTUAL)
Registered Start Date2022-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI